In Autumn 2020, DOAJ will be relaunching with a new website with updated functionality, improved search, and a simplified application form. More information is available on our blog. Our API is also changing.

Hide this message

Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone

Neuropsychiatric Disease and Treatment. 2014;2014(default):527-533

 

Journal Homepage

Journal Title: Neuropsychiatric Disease and Treatment

ISSN: 1176-6328 (Print); 1178-2021 (Online)

Publisher: Dove Medical Press

LCC Subject Category: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system

Country of publisher: United Kingdom

Language of fulltext: English

Full-text formats available: PDF, HTML

 

AUTHORS


Hori H

Yamada K

Kamada D

Shibata Y

Katsuki A

Yoshimura R

Nakamura J

EDITORIAL INFORMATION

Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 16 weeks

 

Abstract | Full Text

Hikaru Hori, Kenji Yamada, Dan Kamada, Yuka Shibata, Asuka Katsuki, Reiji Yoshimura, Jun NakamuraDepartment of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, JapanBackground: This study aims to determine the effectiveness of blonanserin (BNS) on the cognitive and social functions of patients with schizophrenia compared with risperidone (RIS) during acute-phase (8-week) treatment.Methods: A total of 39 schizophrenia inpatients were included in this study. The subjects received either BNS (N=20) or RIS (N=19), and the clinical responses were evaluated periodically. The concomitant use of mood stabilizers was not allowed. Efficacy was assessed with the Positive and Negative Syndrome Scale for schizophrenia. Cognition was assessed using the Brief Assessment of Cognition in Schizophrenia, Japanese-language version. Social function was assessed using the Life Assessment Scale for the Mentally Ill.Results: For both groups, each assessment exhibited a decrease in the mean change from baseline on the Positive and Negative Syndrome Scale. The depression subscale was significantly improved in the BNS group compared with the RIS group at 8 weeks after administration. BNS improved verbal fluency and executive function (cognitive function) and daily living and work skills (social function). Compared with the RIS group, BNS was observed to improve daily living.Conclusion: BNS may improve psychotic symptoms, cognitive function, and daily living in patients with acute-phase schizophrenia. BNS may be superior to RIS in the improvement of daily living.Keywords: risperidone, blonanserin, schizophrenia, cognitive function, social function, acute-phase